Skip to content
TrialScanner

NCT04617054

Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion

Phase 2TerminatedNUVBLead

Registry record

Lead sponsor
Nuvation Bio Inc.
Conditions
Solid Tumor
Primary completion
Dec 6, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04617054 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04617054: Phase II Study of AB-106 to... | TrialScanner